Cetuximab was given for 1 year in the avelumab + cetuximab arm. Crossover at progression to avelumab + cetuximab was allowed. Randomization was 1:1, stratified by PD-L1 and HIV ... defined as the ...

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free ...

HealthDay News — For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overall survival are significantly longer with encorafenib plus cetuximab (EC) plus ...

Methods: Patients diagnosed with p16-negative R/M HNSCC resistant to first-line anti-PD-1 therapy and cetuximab-naïve were enrolled. Patients received oral dalpiciclib 150 mg daily for 21 consecutive ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab ...

Cetuximab dosing. In all indications, cetuximab is administered once a week. The initial dose is 400 mg/m 2. All subsequent weekly doses are 250 mg/m 2.

A first-line regimen combining encorafenib, cetuximab, and mFOLFOX6 significantly increases progression-free survival (12.8 vs. 7.1 months) and overall survival (30.3 vs. 15.1 months) compared to ...

Braftovi (encorafenib) is indicated, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an ...

Median OS was 30.3 months (95% CI, 21.7, Not Estimated) with BRAFTOVI in combination with cetuximab and mFOLFOX6 compared to 15.1 months with chemotherapy with or without bevacizumab (95% CI, 13.7 ...

SCOTTIE SCHEFFLER cruised to another title at the Memorial Open – before being hit with the realities of parenthood. The 28-year-old defended his crown in Ohio with a four-stroke victory over… ...